Ubs Group Ag Annovis Bio, Inc. Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
A detailed history of Ubs Group Ag transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,847 shares of ANVS stock, worth $5,577. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,847
Previous 25,000
92.61%
Holding current value
$5,577
Previous $144,000
90.28%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ANVS
# of Institutions
49Shares Held
1.25MCall Options Held
229KPut Options Held
934K-
Vanguard Group Inc Valley Forge, PA380KShares$1.15 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il103KShares$310,1290.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$304,1410.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.1KShares$299,3240.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$297,5180.01% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $24.7M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...